Ipsen Collaboration was Exicure’s largest revenue line in fiscal 2022, bringing in $17.69M of $28.83M (61%).
| Arrangement Name | FY 2017 | FY 2018 | FY 2019 | FY 2022 |
|---|---|---|---|---|
| Ipsen Collaboration | — | $17.69M | ||
| Abbvie Collaboration | $171.00K | $11.14M | ||
| Purdue Collaboration | — | — | ||
| Dermelix License Agreement | $1.13M | — | ||
| Total | $1.30M | $28.83M |
Exicure brought in $28.83M from its two revenue lines in fiscal 2022, the year ended December 31, 2022. Exicure regrouped these revenue lines after fiscal 2019, so the total does not compare directly with that year's $1.30M. Ipsen Collaboration was the largest at $17.69M (61.4%), ahead of Abbvie Collaboration at $11.14M (38.6%).
Exicure began breaking out Ipsen Collaboration in fiscal 2022, when it brought in $17.69M. Exicure stopped reporting Dermelix License Agreement as a separate revenue line after fiscal 2019, when it brought in $1.13M.
Exicure (XCUR) reports its revenue by arrangement name. In fiscal 2022, Ipsen Collaboration was its largest revenue line, bringing in $17.69M (61.4% of the total), followed by Abbvie Collaboration at $11.14M (38.6%).
Ipsen Collaboration was Exicure's largest revenue line in fiscal 2022, bringing in $17.69M, or 61.4% of the $28.83M total across its two revenue lines.
Every figure comes from Exicure's annual financial filings, as reported. Each line keeps the name Exicure gives it, and years follow its fiscal calendar.
Exicure's revenue by arrangement name goes back to fiscal 2017, with figures through fiscal 2022. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.